Amit M Oza, BSc, MD, MBBS, FRCPC

Dr. Amit Oza is Head of the Division of Medical Oncology & Hematology, and Medical Director of the Cancer Clinical Research Unit at Princess Margaret (PM) Cancer Centre. He is also co-Director of the Drug Development Program at PM Cancer Centre, Scientist at the Ontario Cancer Institute, and Professor of Medicine at University of Toronto. Dr. Oza has been PI and co-investigator in >100 phase I, II and III trials for gynecological cancer and advanced colorectal malignancies. He is the past co-chair of the National Cancer Institute Gynecologic Cancer Steering Committee, and Executive Member of the international Gynecologic Cancer InterGroup. Under his direction, the gynecology group is one of the largest ovarian cancer (OC) clinical trials groups consistently accruing >30% of all patients seen onto clinical trials (>120/yr) at PM Cancer Centre. Under his direction the group has participated or led seminal studies in gynecologic cancers that have led to the approval or use of targeted agents such as PARP inhibitors (olaparib, niraparib) and anti-angiogenic agents (bevacizumab) internationally. Since 2011, he has obtained >$36.9M in peer-reviewed funding and has published >180 articles (all types) in journals, including the New England Journal of Medicine (IF=53); Lancet Oncology (IF=16), and the Journal of Clinical Oncology (IF=16.4).

J Clin Oncol. 2011 May 20;29(15_suppl):5065
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Fossati R, Emons G, Rehman KL, Steffensen KD, Petru E, Gebski V, Burges A, Tubiana-Matthieu N, Hansen M, Vasey PA, Denison U, De Bruyne P, Oza AM
J Clin Oncol. 2011 May 20;29(15_suppl):TPS241
Friedlander M, Stockler MR, King M, Oza AM, Voysey M, Martyn J, Gillies K, Sjoquist KM, Butow P, Australia New Zealand Gynaecological Oncology Group (ANZGOG), Psycho-Oncology Group (PoCoG), Gynecologic Cancer Intergroup (GCIG)
J Clin Oncol. 2011 May 20;29(15_suppl):e13602
Brade AM, Kim SW, Chung C, Wan JF, Southwood B, Chaudary N, Wang L, Milosevic M, Oza AM
J Clin Oncol. 2011 May 20;29(15_suppl):LBA5006
Kristensen G, Perren T, Qian W, Pfisterer J, Ledermann JA, Joly F, Carey MS, Beale PJ, Cervantes A, Oza AM, GCIG
J Clin Oncol. 2011 May 20;29(15_suppl):3068
Schellens JH, Shapiro G, Pavlick AC, Tibes R, Leijen S, Tolaney SM, Diaz-Padilla I, Ramanathan RK, Demuth T, Viscusi J, Cheng JD, Lam R, Xu Y, Oza AM
J Clin Oncol. 2011 May 20;29(15_suppl):3079
Ratain MJ, Schwartz GK, Oza AM, Rudin CM, Kaye SB, De Jonge MJ, Khayat D, Awada A, Sawyer MB, Obel JC, Medioni J, Evans TR, De Greve J, Soetekouw PM, Baurain J, O'Dwyer PJ, Hartman C, Poulart V, Walters IB
J Clin Oncol. 2011 May 20;29(15_suppl):e16572
Degendorfer P, Cole H, Sellmann S, Panzarella T, Brown J, Tinker LM, Gospodarowicz MK, Oza AM
J Clin Oncol. 2004 Jul 15;22(14_suppl):5102
Smit WM, Honkoop AH, Spanik S, Wagnerova M, Huinink WW, Oza AM, Kaye SB, Mull R, Pereno R, Sklenar I
J Clin Oncol. 2004 Jul 15;22(14_suppl):5019
Jasas KV, Fyles A, Elit L, Hoskins PJ, Biagi J, Dubuc-Lissoir J, Matthews S, Dancey J, Eisenhauer E, Oza AM



Co-director, Robert and Maggie Bras and Family Drug Development Program​
Professor, Department of Medicine, University of Toronto
Head, Department of Medical Oncology & Hematology